FDA Offers Advice On Using Patient Reports For Trial Endpoints
This article was originally published in The Gray Sheet
Executive Summary
FDA will support the use of patient-reported data in clinical trials as long as the sponsor makes the measurement tools as robust and meaningful as possible, the agency indicates in a Feb. 3 draft guidance document to industry